
InnoCare’s Mesutoclax Granted Breakthrough Therapy Designation by China’s NMPA
InnoCare’s Mesutoclax Granted Breakthrough Therapy Designation by China’s NMPA In a landmark development for China’s oncology therapeutics landscape, InnoCare Pharma Limited (HKEX: 09969; SSE: 688428), a biopharmaceutical company recognized for…












